Patient Information

YESCARTA® and TECARTUS® can cause side effects that can lead to death.

Call or see your oncologist or get emergency help RIGHT AWAY if you have any of these symptoms:

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heartbeat
- Severe fatigue or weakness

Carry this card with you at all times. SHOW THIS CARD if you go to the emergency room or see any physician.

Tell any healthcare provider that sees you that you are being treated with YESCARTA® or TECARTUS®.

Stay within close proximity (within 2 hours) of the location where you received your treatment for at least 4 weeks after getting YESCARTA® or TECARTUS®.

YESCARTA, the YESCARTA Logo, TECARTUS, the TECARTUS Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.

© 2021 Kite Pharma, Inc. All rights reserved. | REMS-CTF-0026 04/2021
Important Information for Healthcare Providers

Name of treating oncologist: ____________________________________________

Office phone: ________________________________________________________

After-hours phone: ____________________________________________________

Kite CAR T product administered:
- YESCARTA®
- TECARTUS®

Date of Kite CAR T infusion: ____________________________________________

• This patient has received a CD19-directed genetically modified autologous T-cell immunotherapy (CAR T).

• CAR T therapy can cause cytokine release syndrome (CRS) and neurologic toxicities, which may be fatal or life threatening. CRS may involve any organ system.

• Contact the patient’s oncologist immediately for further information.

For more information, please visit www.yescartatecartusrems.com.